Denali Therapeutics Net Worth
Denali Therapeutics Net Worth Breakdown | DNLI |
Denali Therapeutics Net Worth Analysis
Denali Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Denali Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Denali Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Denali Therapeutics' net worth analysis. One common approach is to calculate Denali Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Denali Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Denali Therapeutics' net worth. This approach calculates the present value of Denali Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Denali Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Denali Therapeutics' net worth. This involves comparing Denali Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Denali Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Denali Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Denali Therapeutics' net worth research are outlined below:
| Denali Therapeutics generated a negative expected return over the last 90 days | |
| Denali Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (412.36 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Denali Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Denali Therapeutics Stock Price Up 9.8 percent Should You Buy |
Denali Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Denali Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Denali Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Denali Therapeutics Target Price Consensus
Denali target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Denali Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 18 | Strong Buy |
Most Denali analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Denali stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Denali Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDenali Therapeutics Target Price Projection
Denali Therapeutics' current and average target prices are 23.58 and 39.73, respectively. The current price of Denali Therapeutics is the price at which Denali Therapeutics is currently trading. On the other hand, Denali Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Denali Therapeutics Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Denali Therapeutics Target Price
Know Denali Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Denali Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Denali Therapeutics backward and forwards among themselves. Denali Therapeutics' institutional investor refers to the entity that pools money to purchase Denali Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alliancebernstein L.p. | 2024-09-30 | 3 M | Geode Capital Management, Llc | 2024-09-30 | 3 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 2.9 M | Camber Capital Management Llc | 2024-09-30 | 2 M | Marshall Wace Asset Management Ltd | 2024-09-30 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.7 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.6 M | Goldman Sachs Group Inc | 2024-09-30 | 1.4 M | Bank Of New York Mellon Corp | 2024-09-30 | 1.3 M | Blackrock Inc | 2024-09-30 | 13.8 M | Baillie Gifford & Co Limited. | 2024-09-30 | 13.3 M |
Follow Denali Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.37 B.Market Cap |
|
Project Denali Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | (0.16) | (0.17) |
When accessing Denali Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Denali Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Denali Therapeutics' profitability and make more informed investment decisions.
Evaluate Denali Therapeutics' management efficiency
Denali Therapeutics has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.12. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Denali Therapeutics' Asset Turnover is increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.63 | 13.43 | |
| Tangible Book Value Per Share | 8.63 | 13.43 | |
| Enterprise Value Over EBITDA | (14.37) | (13.65) | |
| Price Book Value Ratio | 2.57 | 2.17 | |
| Enterprise Value Multiple | (14.37) | (13.65) | |
| Price Fair Value | 2.57 | 2.17 | |
| Enterprise Value | 2.6 B | 2.1 B |
The decision-making processes within Denali Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Denali Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denali Therapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 8th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Denali Therapeutics Earnings Estimation Breakdown
The calculation of Denali Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Denali Therapeutics is estimated to be -0.696725 with the future projection ranging from a low of -0.785 to a high of -0.635. Please be aware that this consensus of annual earnings estimates for Denali Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.79 Lowest | Expected EPS | -0.64 Highest |
Denali Therapeutics Earnings Projection Consensus
Suppose the current estimates of Denali Therapeutics' value are higher than the current market price of the Denali Therapeutics stock. In this case, investors may conclude that Denali Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Denali Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 18 | 72.67% | -0.63 | -0.696725 | -2.76 |
Denali Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Denali Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Denali Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Denali Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Denali Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Denali Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Denali Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Denali Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Denali Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -0.61 | -0.63 | -0.02 | 3 | ||
2024-08-01 | 2024-06-30 | -0.69 | -0.59 | 0.1 | 14 | ||
2024-05-07 | 2024-03-31 | -0.7 | -0.78 | -0.08 | 11 | ||
2024-02-27 | 2023-12-31 | -0.8 | -0.86 | -0.06 | 7 | ||
2023-11-07 | 2023-09-30 | -0.8 | -0.72 | 0.08 | 10 | ||
2023-08-08 | 2023-06-30 | -0.68 | 1.3 | 1.98 | 291 | ||
2023-05-08 | 2023-03-31 | -0.7 | -0.8 | -0.1 | 14 | ||
2023-02-27 | 2022-12-31 | -0.79 | -0.75 | 0.04 | 5 | ||
2022-11-03 | 2022-09-30 | -0.81 | -0.84 | -0.03 | 3 | ||
2022-08-08 | 2022-06-30 | -0.55 | -0.48 | 0.07 | 12 | ||
2022-05-05 | 2022-03-31 | -0.51 | -0.53 | -0.02 | 3 | ||
2022-02-28 | 2021-12-31 | -0.41 | -0.62 | -0.21 | 51 | ||
2021-11-04 | 2021-09-30 | -0.47 | -0.69 | -0.22 | 46 | ||
2021-08-04 | 2021-06-30 | -0.41 | -0.5 | -0.09 | 21 | ||
2021-05-03 | 2021-03-31 | -0.34 | -0.58 | -0.24 | 70 | ||
2021-02-25 | 2020-12-31 | 0.01 | 1.91 | 1.9 | 19000 | ||
2020-11-05 | 2020-09-30 | 2.59 | -0.54 | -3.13 | 120 | ||
2020-08-07 | 2020-06-30 | -0.6 | -0.56 | 0.04 | 6 | ||
2020-05-07 | 2020-03-31 | -0.57 | -0.55 | 0.02 | 3 | ||
2020-02-27 | 2019-12-31 | -0.58 | -0.56 | 0.02 | 3 | ||
2019-11-06 | 2019-09-30 | -0.56 | -0.48 | 0.08 | 14 | ||
2019-08-06 | 2019-06-30 | -0.46 | -0.61 | -0.15 | 32 | ||
2019-05-08 | 2019-03-31 | -0.4 | -0.41 | -0.01 | 2 | ||
2019-03-12 | 2018-12-31 | -0.11 | 0.79 | 0.9 | 818 | ||
2018-11-08 | 2018-09-30 | -0.25 | -0.38 | -0.13 | 52 | ||
2018-08-09 | 2018-06-30 | -0.2 | -0.59 | -0.39 | 195 | ||
2018-05-11 | 2018-03-31 | -0.03 | -0.26 | -0.23 | 766 | ||
2018-03-19 | 2017-12-31 | -0.2 | -0.74 | -0.54 | 270 | ||
2017-12-08 | 2017-09-30 | 0 | -0.53 | -0.53 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -2.36 | -2.36 | 0 |
Denali Therapeutics Corporate Management
| Peter Chin | Senior Affairs | Profile | |
| Carole MD | Chief Development | Profile | |
| Mark Rowen | Vice Development | Profile | |
| Chris Walsh | General Counsel | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.